A prospective study of the natural course of cytomegalovirus infection and disease in renal allograft recipients

Transplantation

Volumn 70, Issue 8, 2000, Pages 1166-1174

  Sagedal, Solbjørg ^a,b   Nordal, Knut P ^a   Hartmann, Anders ^a   Degré, Miklos ^a   Holter, Ellen ^a   Foss, Aksel ^a   Osnes, Kåre ^a   Leivestad, Torbjørn ^a   Fauchald, Per ^a   Rollag, Halvor ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; COTRIMOXAZOLE; CYCLOSPORIN A; GANCICLOVIR; STEROID; VIRUS ANTIGEN;

ADOLESCENT; ADULT; AGED; ARTICLE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GRAFT REJECTION; HEPATITIS; HUMAN; INCIDENCE; KIDNEY ALLOGRAFT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RECURRENT INFECTION; RISK FACTOR; SEROLOGY;

EID: 0034721847     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200010270-00007     Document Type: Article

References (30)

1. Impact of cytomegalovirus infection on organ transplant recipients
2. Clinical course of cytomegalovirus (CMV) viremia with and without ganciclovir treatment in CMV-seropositive kidney transplant recipients
3. Diagnostic markers and risk factors of cytomegalovirus infection and disease in renal allograft recipients
4. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation
5. Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3
6. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients
7. Cytomegalovirus infection: An etiological factor for rejection?
8. Treatment of recurrent cytomegalovirus disease in patients receiving solid organ transplants
9. Influence of cytomegalovirus antibody status on graft survival in renal transplantation
10. Diagnosis of cytomegalovirus infection in kidney transplant recipients by a quantitative RNA-DNA hybrid capture assay for cytomegalovirus DNA in leukocytes
11. A strong impact of matching for a limited number of HLA-DR antigens on graft survival and rejection episodes: A single center study of first cadaveric kidneys to non-sensitized recipients
12. Monitored high-dose azathioprine treatment reduces acute rejection episodes after renal transplantation
13. Cytomegalovirus antigenemia as a useful marker of symptomatic cytomegalovirus infection after renal transplantation: A report of 130 consecutive patients
14. Symptomatic cytomegalovirus infection in seropositive kidney recipients: Reinfection with donor virus rather than reactivation of recipient virus
15. Immunologic parameters as predictive factors of cytomegalovirus disease in renal allograft recipients
16. The role of the TNF-system and interleukin 10 during CMV-infection in renal allograft recipients
17. Cytomegalovirus pneumonia in renal transplant patients
18. Quantitative polymerase chain reaction to predict occurrence of symptomatic cytomegalovirus infection and assess response to ganciclovir therapy in renal transplant recipients
19. Monitoring and diagnosis of cytomegalovirus infection in renal transplantation
20. Diagnosing cytomegalovirus disease in CMV seropositive renal allograft recipients: A comparison between the detection of CMV DNAemia by polymerase chain reaction and antigenemia by CMV pp65 assay
21. Factors influencing the occurrence of active cytomegalovirus (CMV) infections after organ transplantation
22. Quantity of human cytomegalovirus (CMV) DNAemia as a risk factor for CMV disease in renal allograft recipients: Relationship with donor/recipient CMV serostatus, receipt of augmented methylprednisolone and antithymocyte globulin (ATG)
23. Human herpesvirus 6 reactivation is associated with cytomegalovirus infection and syndromes in kidney transplant recipients at risk for primary cytomegalovirus infection
24. Importance of simultaneous active cytomegalovirus and Epstein-Barr virus infection in renal transplantation
25. Control of cytomegalovirus-associated morbidity in renal transplant patients using intensive monitoring and either preemptive or deferred therapy
26. Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients
27. Cytomegalovirus preemptive therapy with ganciclovir in renal transplant patients treated with OKT3
28. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients: A randomized controlled trial
29. Preemptive therapy with ganciclovir for early high-risk CMV infection allows effective treatment with antithymocyte globulin of steroid-resistant rejection after renal transplantation
30. The prognostic significance of positive CMV cultures during surveillance of renal transplant recipients